✦ LIBER ✦

ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection

✍ Scribed by Andreone, Pietro; Colombo, Massimo G.; Enejosa, Jeffrey V.; Koksal, Iftihar; Ferenci, Peter; Maieron, Andreas; Müllhaupt, Beat; Horsmans, Yves; Weiland, Ola; Reesink, Henk W.; Rodrigues, Lino; Hu, Yiran B.; Podsadecki, Thomas; Bernstein, Barry

Book ID: 121820787
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 709 KB
Volume: 147
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2014.04.045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1187 ABT-450/RITONAVIR (ABT-450/R) COMBI

1187 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

✍ Lawitz, E.; Poordad, F.; DeJesus, E.; Kowdley, K.; Gaultier, I.; Cohen, D.; Xie, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 100 KB

13 A 12-WEEK INTERFERON-FREE REGIMEN OF

13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS

✍ E. Lawitz; F. Poordad; K.V. Kowdley; D. Jensen; D.E. Cohen; S. Siggelkow; K. Wik 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 105 KB

514 Interferon-Free Regimens of Abt-450/

514 Interferon-Free Regimens of Abt-450/R, Abt-267, Abt-333, and Ribavirin Achieve High Sustained Virologic Response 4 Weeks Post-Treatment (SVR4) Rates in Patients With Chronic HCV Genotype 1 Regardless of Race, Ethnicity, or Other Baseline Characteristics

✍ Rodriguez-Torres, Maribel; Nunes, Frederick; Cohen, Daniel; Xie, Wangang; Marinc 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 376 KB

1206 ABT-072 OR ABT-333 COMBINED WITH PE

1206 ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

✍ Poordad, F.; Lawitz, E.; DeJesus, E.; Kowdley, K.V.; Gaultier, I.; Cohen, D.E.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB